Serum diiodotyrosine – a biomarker to differentiate destructive thyroiditis from Graves’ disease

in European Journal of Endocrinology
View More View Less
  • 1 Department of General Medicine, National Defense Medical College, Tokorozawa, Saitama, Japan
  • | 2 ASKA Pharmaceutical Co., Ltd., Minato-ku, Tokyo, Japan
  • | 3 ASKA Pharma Medical Co., Ltd., Fujisawa, Kanagawa, Japan

Correspondence should be addressed to N Fujita; Email: raoh0615@gmail.com
Restricted access

Objective

Conventional diagnostic methods are limited in their ability to differentiate destructive thyroiditis from Graves’ disease. We hypothesised that serum diiodotyrosine (DIT) and monoiodotyrosine (MIT) levels could be biomarkers for differentiating destructive thyroiditis from Graves’ disease.

Design

Patients with destructive thyroiditis (n  = 13) and Graves’ disease (n  = 22) were enrolled in this cross-sectional study.

Methods

We assayed the serum DIT and MIT levels using liquid chromatography-tandem mass spectrometry. A receiver operating characteristic (ROC) curve analysis was used to determine the sensitivity and specificity of the serum DIT and MIT levels as biomarkers for differentiating destructive thyroiditis from Graves’ disease.

Results

The serum DIT and MIT levels were significantly higher in patients with destructive thyroiditis than in those with Graves’ disease. The ROC curve analysis showed that the serum DIT levels (≥359.9 pg/mL) differentiated destructive thyroiditis from Graves’ disease, significantly, with 100.0% sensitivity and 95.5% specificity (P < 0.001). The diagnostic accuracy of the serum MIT levels (≥119.4 pg/mL) was not as high as that of the serum DIT levels (sensitivity, 84.6%; specificity, 77.3%; P = 0.001).

Conclusions

The serum DIT levels may serve as a novel diagnostic biomarker for differentiating destructive thyroiditis from Graves’ disease.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 2401 2401 343
Full Text Views 96 96 10
PDF Downloads 154 154 23
  • 1

    Amino N, Yabu Y, Miki T, Morimoto S, Kumahara Y, Mori H, Iwatani Y, Nishi K, Nakatani K, Miyai K. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves’ disease and destruction-induced thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism 1981 53 113116. (https://doi.org/10.1210/jcem-53-1-113)

    • Search Google Scholar
    • Export Citation
  • 2

    Hiraiwa T, Ito M, Imagawa A, Isotani H, Takamatsu J, Kuma K, Miyauchi A, Hanafusa T. High diagnostic value of a radioiodine uptake test with and without iodine restriction in Graves’ disease and silent thyroiditis. Thyroid 2004 14 531535. (https://doi.org/10.1089/1050725041517011)

    • Search Google Scholar
    • Export Citation
  • 3

    Osaki Y, Sakurai K, Arihara Z, Hata M, Fukazawa H. Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves’ disease. Endocrine Journal 2012 59 173177. (https://doi.org/10.1507/endocrj.ej11-0279)

    • Search Google Scholar
    • Export Citation
  • 4

    Morris LF, Waxman AD, Braunstein GD. Accuracy considerations when using early (four- or six-hour) radioactive iodine uptake to predict twenty-four-hour values for radioactive iodine dosage in the treatment of Graves’ disease. Thyroid 2000 10 779787. (https://doi.org/10.1089/thy.2000.10.779)

    • Search Google Scholar
    • Export Citation
  • 5

    Barbesino G, Tomer Y. Clinical Review: Clinical utility of TSH receptor antibodies. Journal of Clinical Endocrinology and Metabolism 2013 98 22472255. (https://doi.org/10.1210/jc.2012-4309)

    • Search Google Scholar
    • Export Citation
  • 6

    Kamijo K, Murayama H, Uzu T, Togashi K, Kahaly GJ. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves’ disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 2010 20 851856. (https://doi.org/10.1089/thy.2010.0059)

    • Search Google Scholar
    • Export Citation
  • 7

    Kamijo K Study on cutoff value setting for differential diagnosis between Graves’ disease and painless thyroiditis using the TRAb (Elecsys TRAb) measurement via the fully automated electrochemiluminescence immunoassay system. Endocrine Journal 2010 57 895902. (https://doi.org/10.1507/endocrj.k10e-199)

    • Search Google Scholar
    • Export Citation
  • 8

    Yoshimura Noh J, Miyazaki N, Ito K, Takeda K, Hiramatsu S, Morita S, Miyauchi A, Murakami T, Inomata K & Noguchi S et al.Evaluation of a new rapid and fully automated electrochemiluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid 2008 18 11571164. (https://doi.org/10.1089/thy.2008.0119)

    • Search Google Scholar
    • Export Citation
  • 9

    Amino N, Yabu Y, Miyai K, Fujie T, Azukizawa M, Onishi T, Kumahara Y. Differentiation of thyrotoxicosis induced by thyroid destruction from Graves’ disease. Lancet 1978 2 344346. (https://doi.org/10.1016/s0140-6736(7892943-4)

    • Search Google Scholar
    • Export Citation
  • 10

    Sugimoto T, Momotani N, Iino S, Ito K. Clinical significance of the measurement of the urinary concentration of iodine in differentiating silent thyroiditis from Graves’ disease. Nihon Naibunpi Gakkai Zasshi 1994 70 10831092 (in Japanese). (https://doi.org/10.1507/endocrine1927.70.10_1083)

    • Search Google Scholar
    • Export Citation
  • 11

    Ota H, Amino N, Morita S, Kobayashi K, Kubota S, Fukata S, Kamiyama N, Miyauchi A. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves’ disease. Clinical Endocrinology 2007 67 4145. (https://doi.org/10.1111/j.1365-2265.2007.02832.x)

    • Search Google Scholar
    • Export Citation
  • 12

    Uchida T, Shigihara N, Takeno K, Komiya K, Goto H, Abe H, Sato J, Honda A, Fujitani Y, Watada H. Characteristics of patients with Graves’ disease and intrathyroid hypovascularity compared to painless thyroiditis. Journal of Ultrasound in Medicine 2014 33 17911796. (https://doi.org/10.7863/ultra.33.10.1791)

    • Search Google Scholar
    • Export Citation
  • 13

    Mukhtar ED, Smith BR, Pyle GA, Hall R, Vice P. Relation of thyroid-stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs. Lancet 1975 1 713715. (https://doi.org/10.1016/s0140-6736(7591629-3)

    • Search Google Scholar
    • Export Citation
  • 14

    Pearce EN, Farwell AP, Braverman LE. Thyroiditis. New England Journal of Medicine 2003 348 26462655. (https://doi.org/10.1056/NEJMra021194)

  • 15

    Nelson JC, Weiss RM, Palmer FJ, Lewis JE, Wilcox RB. Serum diiodotyrosine. Journal of Clinical Endocrinology and Metabolism 1975 41 11181124. (https://doi.org/10.1210/jcem-41-6-1118)

    • Search Google Scholar
    • Export Citation
  • 16

    Tan SA, Lewis JE, Berk LS, Wilcox RB. Extrathyroidal physiology of monoiodotyrosine in humans. Clinical Physiology and Biochemistry 1990 8 109115.

    • Search Google Scholar
    • Export Citation
  • 17

    Meinhold H, Beckert A, Wenzel KW. Circulating diiodotyrosine: studies of its serum concentration, source, and turnover using radioimmunoassay after immunoextraction. Journal of Clinical Endocrinology and Metabolism 1981 53 11711178. (https://doi.org/10.1210/jcem-53-6-1171)

    • Search Google Scholar
    • Export Citation
  • 18

    Meinhold H, Olbricht T, Schwartz-Porsche D. Turnover and urinary excretion of circulating diiodotyrosine. Journal of Clinical Endocrinology and Metabolism 1987 64 794800. (https://doi.org/10.1210/jcem-64-4-794)

    • Search Google Scholar
    • Export Citation
  • 19

    Afink G, Kulik W, Overmars H, de Randamie J, Veenboer T, van Cruchten A, Craen M, Ris-Stalpers C. Molecular characterization of iodotyrosine dehalogenase deficiency in patients with hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2008 93 48944901. (https://doi.org/10.1210/jc.2008-0865)

    • Search Google Scholar
    • Export Citation
  • 20

    Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA & Stan MN et al.2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016 26 13431421. (https://doi.org/10.1089/thy.2016.0229)

    • Search Google Scholar
    • Export Citation
  • 21

    Uchida T, Suzuki R, Kasai T, Onose H, Komiya K, Goto H, Takeno K, Ishii S, Sato J & Honda A et al.Cutoff value of thyroid uptake of (99m) Tc-pertechnetate to discriminate between Graves’ disease and painless thyroiditis: a single center retrospective study. Endocrine Journal 2016 63 143149. (https://doi.org/10.1507/endocrj.EJ15-0441)

    • Search Google Scholar
    • Export Citation
  • 22

    Wang K, Sun YN, Liu JY, Zhang L, Ye Y, Lin LX, Yan YQ, Chen ZP. The impact of iodine excess on thyroid hormone biosynthesis and metabolism in rats. Biological Trace Element Research 2009 130 7285. (https://doi.org/10.1007/s12011-009-8315-z)

    • Search Google Scholar
    • Export Citation